Peter Tummino, President of R&D at Nimbus Therapeutics – Drugging the Undruggable, The TYK2 Success Story, and Overhyping AI in Drug Discovery

Peter Tummino, President of R&D at Nimbus Therapeutics – Drugging the Undruggable, The TYK2 Success Story, and Overhyping AI in Drug Discovery

In this episode, I talked with Peter Tummino, President of Research and Development at Nimbus Therapeutics, where he discussed what it takes to build a successful biotech R&D engine. Peter shares his insights on company culture and its impact on drug discovery, the challenges of targeting difficult-to-drug proteins, and the lessons he’s learned from decades in pharma and biotech. He also reflects on leadership in R&D, the evolution of drug discovery strategies, and what excites him most about the future of the industry.

Here's what you are in for:

  • How does company culture influence scientific innovation in biotech?
  • What are the biggest challenges in drug discovery, and how can teams overcome them?
  • What lessons has Peter learned from his time at GSK, AstraZeneca, and Nimbus?
  • What does the future of small molecule drug development look like?


Timestamps:

01:09 Career Journey

05:15 Challenges and Lessons Learned

08:33 Overview of Nimbus Therapeutics

10:14 Exciting Clinical Trials at Nimbus

11:39 Culture at Nimbus Therapeutics

15:25 Industry Observations and AI

19:16 Recruitment Insights and Experiences

25:06 Quick Fire Questions


About Peter

Dr. Peter Tummino is the President of Research and Development at Nimbus Therapeutics, a clinical-stage biotech that designs and develops novel small molecule medicines targeting difficult-to-drug proteins. He has been in small molecule drug discovery for over thirty years, including the past 6 with Nimbus.

While at GSK, he contributed to the discovery of the approved oncology drugs (Dabrafenib, Trametinib, and Daprodustat for chronic kidney disease). At Nimbus, he led discovery during the development of Zaso-ci-tinib, which is currently in Phase 2 & 3 for psoriasis and other I&I clinical indications.


Connect with Peter

LinkedIn: https://www.linkedin.com/in/peter-tummino-7496753/

Nimbus Therapeutics: https://www.nimbustx.com/


About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/



Opinions and comments expressed by the guest do not represent the company and are fully their own.



Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(71)

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Jun 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Mai 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Mai 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Mai 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mar 42min

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

In this episode, I talked with Volker Wacheck, SVP & Head of Clinical Development at Taiho Oncology, where he shared how a PI role in Vienna led him into industry, and why the hardest part wasn’t leav...

9 Mar 29min

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

In this episode, I talked with Dr. Dena Grayson, a physician–scientist with over two decades in biotech drug development. At the time of this recording, she was SVP and Head of Clinical Development at...

24 Feb 31min

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space.Richard’s career began in ...

26 Jan 35min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
rss-skravla-gar
pengepodden-2
livet-pa-veien-med-jan-erik-larssen
finansredaksjonen
utbytte
okonomiamatorene
rss-pa-konto
tid-er-penger-en-podcast-med-peter-warren
morgenkaffen-med-finansavisen
liberal-halvtime
lederpodden
pengesnakk
rss-impressions-2
stormkast-med-valebrokk-stordalen